Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Recruiting 2Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 54Recurrence 5Neoplasms, Plasma Cell 3Immunoglobulin Light-chain Amyloidosis 3Amyloidosis 2Renal Insufficiency 1Plasmablastic Lymphoma 1Kidney Failure, Chronic 1Corneal Diseases 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recurrence × belantamab mafodotin × Clear all
NCT05714839 2026-05-22

DREAMM-20

GlaxoSmithKline

Phase 1/2 Recruiting
152 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05064358 2026-05-05

DREAMM 14

GlaxoSmithKline

Phase 2 Completed
177 enrolled 37 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting
300 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05922501 2026-01-14

ISABELA

Massachusetts General Hospital

Phase 2 Recruiting
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT04398680 2025-12-04

DREAMM 13

GlaxoSmithKline

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡